Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPAR1 | Q92633 | 3/20 | 0.34 |
| ▸ | LPAR3 | Q9UBY5 | 2/20 | 0.34 |
| ▸ | MLYCD | O95822 | 1/20 | 0.33 |
| ▸ | TET3 | O43151 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | FBXL19 | Q6PCT2 | 1/20 | 0.31 |
| ▸ | CXXC5 | Q7LFL8 | 1/20 | 0.31 |
| ▸ | KDM2B | Q8NHM5 | 1/20 | 0.31 |
| ▸ | CXXC4 | Q9H2H0 | 1/20 | 0.31 |
| ▸ | KDM2A | Q9Y2K7 | 1/20 | 0.31 |
| ▸ | CA1 | P00915 | 2/20 | 0.30 |
| ▸ | CA2 | P00918 | 2/20 | 0.30 |
| ▸ | CA9 | Q16790 | 2/20 | 0.30 |
| ▸ | CA12 | O43570 | 1/20 | 0.30 |
| ▸ | CA3 | P07451 | 1/20 | 0.30 |
| ▸ | CA4 | P22748 | 1/20 | 0.30 |
| ▸ | CA6 | P23280 | 1/20 | 0.30 |
| ▸ | CA5A | P35218 | 1/20 | 0.30 |
| ▸ | CA7 | P43166 | 1/20 | 0.30 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5091 | 0.84 | CA1 (0.45) | LPAR1LPAR3CA1CA2CA9 | |
| SCHEMBL13574619 | 0.75 | CA1 (0.48) | CA1CA2CA9CA12CA3 | |
| SCHEMBL13474635 | 0.73 | LPL (0.38) | CA1CA2CA9CA12CA3 | |
| SCHEMBL14267971 | 0.73 | PTGS2 (0.35) | CA1CA2CA9CA12CA3 | |
| SCHEMBL2084 | 0.71 | HDAC1 (0.45) | LPAR1LPAR3MLYCDKDM4EGAA | |
| SCHEMBL10282788 | 0.70 | LPL (0.40) | CA1CA2CA9CA12CA3 | |
| SCHEMBL13622824 | 0.70 | SMN1; SMN2 (0.42) | KMT2ACA1CA2CA9CA12 | |
| SCHEMBL12512630 | 0.69 | LPL (0.33) | — | |
| SCHEMBL3678803 | 0.69 | LPAR1 (0.53) | LPAR1LPAR3MLYCDTET3KMT2A | |
| SCHEMBL23235351 | 0.69 | AKR1C3 (0.33) | LPAR1LPAR3MLYCDCA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120289522-A1 | COMPOUNDS AS LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS | AMIRA PHARMACEUTICALS INC. | 2012-11-15 | — | — | US | disclosed |
| WO-2012138797-A1 | 3- OR 5 - BI PHENYL - 4 - YLISOXAZOLE - BASED COMPOUNDS USEFUL FOR THE TREATMENT OF FIBROSIS, PAIN, CANCER AND RESPIRATORY, ALLERGIC, NERVOUS SYSTEM OR CARDIOVASCULAR DISORDERS | AMIRA PHARMACEUTICALS, INC. (US) | 2012-10-11 | — | — | WO | disclosed |
| WO-2011041462-A2 | POLYCYCLIC COMPOUNDS AS LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS | AMIRA PHARMACEUTICALS, INC. (US) | 2011-04-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120289522-A1 | COMPOUNDS AS LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS | LPAR1, LPAR2, LPAR4 | LPAR1 1/4885LPAR3 5/4885MLYCD 3165/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.